フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel...
Satellos Bioscience Inc. Opens the Market PR Newswire TORONTO, May 15, 2024 TORONTO, May 15, 2024 /PRNewswire/ - Frank Gleeson Co-Founder and...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule...
- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule...
- Engaged CRO for first-in-human SAT-3247 Phase 1 clinical study - Initiated GLP toxicity studies and GMP manufacturing of SAT-3247 - Continues...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule...
- Orally administered SAT-3247 demonstrates efficacy across three mouse models of muscle degeneration - Efficacy in muscle injury model...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL), a public biotech company developing new small molecule therapeutic approaches...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約